Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder.

Christopher T Rentsch; Samantha G Malone; Mingjian Shi; Michael Setzer; Zachary Piserchia; Emma L. Winterlind; Mehdi Farokhnia; John Tazare; Amy C Justice; David A Fiellin; Lorenzo Leggio; Henry R Kranzler; J. R. Gray

doi:10.1111/acer.70247

March 1, 2026

Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder.

View at Publisher

Ask AI

Bookmark

Share

Key Points

To align genomic findings with clinical data for enhancing treatment options for alcohol use disorder (AUD).
Integrated genomic findings with real-world clinical data.
Identified and prioritized drug repurposing candidates.
Focused on candidates suited for randomized trials.
Provided an efficient method for identifying candidates.
Highlight potential pharmacotherapies for AUD.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This approach identifies drug repurposing candidates for alcohol use disorder, suggesting new treatment evaluations.

Abstract

This approach, which aligns genomic findings with real-world clinical data, provides an efficient method for identifying promising drug repurposing candidates and prioritizing those that merit evaluation in randomized trials to ultimately advance pharmacotherapies for AUD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rentsch et al. (2026) studied this question.

synapsesocial.com/papers/69b3ac7002a1e69014cce1c0 https://doi.org/10.1111/acer.70247

View at Publisher

Ask AI

Bookmark

Share

Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading